These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 31082669)

  • 21. The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience.
    De Luca R; Costa RP; Tripoli V; Murabito A; Cicero G
    Oncology; 2018; 94(3):161-166. PubMed ID: 29241166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer.
    Sternberg CN; Saad F; Graff JN; Peer A; Vaishampayan UN; Leung E; Rosenbaum E; Gurney H; Epstein RJ; Davis ID; Wu B; Trandafir L; Wagner VJ; Hussain M
    Ann Oncol; 2020 Feb; 31(2):257-265. PubMed ID: 31959342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
    Heidenreich A; Gillessen S; Heinrich D; Keizman D; O'Sullivan JM; Carles J; Wirth M; Miller K; Reeves J; Seger M; Nilsson S; Saad F
    BMC Cancer; 2019 Jan; 19(1):12. PubMed ID: 30612558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.
    Yu EY; Kolinsky MP; Berry WR; Retz M; Mourey L; Piulats JM; Appleman LJ; Romano E; Gravis G; Gurney H; Bögemann M; Emmenegger U; Joshua AM; Linch M; Sridhar S; Conter HJ; Laguerre B; Massard C; Li XT; Schloss C; Poehlein CH; de Bono JS
    Eur Urol; 2022 Jul; 82(1):22-30. PubMed ID: 35397952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with
    Turner PG; Jain S; Cole A; Grey A; Mitchell D; Prise KM; Hounsell AR; McGarry CK; Biggart S; O'Sullivan JM
    Clin Cancer Res; 2021 Aug; 27(16):4549-4556. PubMed ID: 34187853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
    Hansen AR; Tannock IF; Templeton A; Chen E; Evans A; Knox J; Prawira A; Sridhar SS; Tan S; Vera-Badillo F; Wang L; Wouters BG; Joshua AM
    Oncologist; 2019 Sep; 24(9):1188-1194. PubMed ID: 30952818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE).
    Pan E; Xie W; Ajmera A; Araneta A; Jamieson C; Folefac E; Hussain A; Kyriakopoulos CE; Olson A; Parikh M; Parikh R; Saraiya B; Ivy SP; Van Allen EM; Lindeman NI; Kochupurakkal BS; Shapiro GI; McKay RR
    Mol Cancer Ther; 2023 Apr; 22(4):511-518. PubMed ID: 36780008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial.
    van Dodewaard-de Jong JM; de Klerk JMH; Bloemendal HJ; Oprea-Lager DE; Hoekstra OS; van den Berg HP; Los M; Beeker A; Jonker MA; O'Sullivan JM; Verheul HMW; van den Eertwegh AJM
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1319-1327. PubMed ID: 28421240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study.
    Matsubara N; Kimura G; Uemura H; Uemura H; Nakamura M; Nagamori S; Mizokami A; Kikukawa H; Hosono M; Kinuya S; Krissel H; Siegel J; Kakehi Y
    Int J Clin Oncol; 2020 Apr; 25(4):720-731. PubMed ID: 31823152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
    Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
    Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.
    McGann S; Horton ER
    Ann Pharmacother; 2015 Apr; 49(4):469-76. PubMed ID: 25573268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer.
    Crabb SJ; Birtle AJ; Martin K; Downs N; Ratcliffe I; Maishman T; Ellis M; Griffiths G; Thompson S; Ksiazek L; Khoo V; Jones RJ
    Invest New Drugs; 2017 Oct; 35(5):599-607. PubMed ID: 28144789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.
    Heath E; Heilbrun L; Mannuel H; Liu G; Lara P; Monk JP; Flaig T; Zurita A; Mack P; Vaishampayan U; Stella P; Smith D; Bolton S; Hussain A; Al-Janadi A; Silbiger D; Usman M; Ivy SP
    Oncologist; 2019 Sep; 24(9):1149-e807. PubMed ID: 31152080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.
    Parker C; Finkelstein SE; Michalski JM; O'Sullivan JM; Bruland Ø; Vogelzang NJ; Coleman RE; Nilsson S; Sartor O; Li R; Seger MA; Bottomley D
    Eur Urol; 2016 Nov; 70(5):875-883. PubMed ID: 27344296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer.
    Thakur MK; Heilbrun L; Dobson K; Boerner J; Stark K; Li J; Smith D; Heath E; Fontana J; Vaishampayan U
    Clin Genitourin Cancer; 2018 Jun; 16(3):e695-e703. PubMed ID: 29534939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal usage of radium-223 in metastatic castration-resistant prostate cancer.
    Cha TL; Wu TT; Vogelzang NJ; Huang CY; Huang SP; Lin CC; Ou YC; Pang ST; Shen DH; Wu WJ; Chang WY
    J Formos Med Assoc; 2017 Nov; 116(11):825-836. PubMed ID: 29046247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
    de Kouchkovsky I; Rao A; Carneiro BA; Zhang L; Lewis C; Phone A; Small EJ; Friedlander T; Fong L; Paris PL; Ryan CJ; Szmulewitz RZ; Aggarwal R
    Clin Cancer Res; 2022 Apr; 28(8):1531-1539. PubMed ID: 35176163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current approaches to incorporation of radium-223 in clinical practice.
    Parker C; Heidenreich A; Nilsson S; Shore N
    Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):37-47. PubMed ID: 29298991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.
    Corn PG; Heath EI; Zurita A; Ramesh N; Xiao L; Sei E; Li-Ning-Tapia E; Tu SM; Subudhi SK; Wang J; Wang X; Efstathiou E; Thompson TC; Troncoso P; Navin N; Logothetis CJ; Aparicio AM
    Lancet Oncol; 2019 Oct; 20(10):1432-1443. PubMed ID: 31515154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (
    Batra JS; Niaz MJ; Whang YE; Sheikh A; Thomas C; Christos P; Vallabhajosula S; Jhanwar YS; Molina AM; Nanus DM; Osborne JR; Bander NH; Tagawa ST
    Urol Oncol; 2020 Nov; 38(11):848.e9-848.e16. PubMed ID: 32600929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.